{
  "chapter": "Endocrinology-Diabetes Mellitus-I",
  "questions": [
    {
      "q_no": 1,
      "question": "A 50-year-old woman visits her physician for a routine check-up. Her laboratory results reveal a fasting plasma glucose level of 104 mg/dL (5.8 mmol/L) and an HbA1c level of 44 mmol/mol (6.2%). Which of the following statements about her condition is correct?",
      "options": {
        "A": "She is diagnosed with type 2 diabetes mellitus.",
        "B": "She meets the criteria for pre-diabetes based on her fasting plasma glucose level.",
        "C": "Her HbA1c level indicates normal glucose metabolism.",
        "D": "She requires immediate insulin therapy."
      },
      "correct_answer": "B",
      "explanation": "category of impaired fasting glucose ( ≥ 100 mg/dL) , indicating a pre-diabetic state. Additionally, her HbA1c level of 44 mmol/mol (approximately 6.2%) supports the diagnosis of pre-diabetes rather than normal glucose metabolism. Pre-diabetes: Pre-diabetes involves elevated blood glucose levels that are not high enough for a type 2 diabetes diagnosis. Also referred to as: Impaired Glucose Tolerance (IGT) Impaired Fasting Glucose (IFG) Difference between IFG and IGT Criteria Impaired Fasting Glucose (IFG) Impaired Glucose Tolerance (IGT) Indicates Poor glucose regulation after fasting Impaired insulin sensitivity or inadequate insulin production after sugar intake Pathophysiology: IFG suggests early insulin resistance or beta-cell dysfunction. IGT indicates a more pronounced glucose metabolism impairment. Diagnostic Criteria for Pre-diabetes (Option B) Criterion Definition Impaired Fasting Glucose (IFG) Fasting plasma glucose: ≥ 6.1 mmol/L (110 mg/dL) < 7.0 mmol/L (126 mg/dL) (Option A ruled out) The American Diabetes Association suggests a lower limit of ≥ 100 mg/dL (5.6 mmol/L) . Impaired Glucose Tolerance (IGT) Fasting plasma glucose: < 126 mg/dL (7.0 mmol/L) 2-hour glucose after 75 g oral glucose drink: 140–200 mg/dL (7.8–11.1 mmol/L). HbA1c Criteria (Option C ruled out) NICE guidelines: 6.0% to 6.4% (42–47 mmol/mol) American Diabetes Association: 5.7% to 6.4% (39–47 mmol/mol) Significance of Pre-diabetes Increased Diabetes Risk : Higher likelihood of developing type 2 diabetes. Cardiovascular Disease Risk : Linked to macrovascular issues (e.g., atherosclerosis), increasing risks of: Myocardial infarction Stroke Peripheral vascular disease Management of Pre-diabetes (Option D ruled out) Management Strategy Details Lifestyle Modifications Weight Management : Healthy weight through diet and exercise. Healthy Eating : Balanced diet low in saturated fat, cholesterol, and sugars; high in fiber, fruits, and vegetables. Physical Activity : At least 150 minutes of moderate-intensity aerobic exercise weekly. Cardiovascular Risk Management Aggressive management of hypertension and dyslipidemia to reduce cardiovascular risks. Medication Consider metformin to delay progression to type 2 diabetes, if necessary. Screening for Pre-diabetes Regular screening is advised for individuals with risk factors such as: Obesity Family history of diabetes Certain ethnic backgrounds History of gestational diabetes",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 2,
      "question": "Which of the following is most characteristic of Type 3 Diabetes (T3DM)?",
      "options": {
        "A": "Insulin resistance affecting the muscles and fat tissue",
        "B": "Primarily affects cognitive functions like memory due to insulin resistance in the brain",
        "C": "No connection to Alzheimer's disease",
        "D": "Treated solely through oral hypoglycemic agents"
      },
      "correct_answer": "B",
      "explanation": "brain neurodegenerative processes. Type 3 Diabetes (T3DM): Definition: A term primarily linked with Alzheimer's disease (AD), describing insulin resistance and deficiency affecting the brain. (Option C ruled out) Characteristics of Type 3 Diabetes: Characteristic Details Insulin Resistance in Brain Neurons cannot effectively respond to insulin, impairing cognitive functions like memory. Connection to AD AD is associated with impaired insulin signalling, leading some to label it as \"diabetes of the brain.\" Pathophysiology Impaired insulin signalling leads to amyloid-beta plaques, tau tangles, oxidative stress, and neuroinflammation, contributing to neurodegeneration and cognitive decline. Implications for Treatment: Treatment Approach (Option D ruled out) Details Insulin Sensitizers Medications improving insulin sensitivity could have neuroprotective effects. Lifestyle Interventions Diet and exercise targeting metabolic health may slow AD progression and benefit cognition. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769828/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7246646/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 3,
      "question": "Which of the following is most characteristic of Latent Autoimmune Diabetes in Adulthood (LADA)? β -cell destruction similar to type 1 diabetes β -cell destruction and eventual insulin requirement",
      "options": {
        "A": "Rapid",
        "B": "Absence of islet autoantibodies",
        "C": "Gradual",
        "D": "Complete management through lifestyle modifications and oral antidiabetic agents"
      },
      "correct_answer": "C",
      "explanation": "β -cell destruction and eventual insulin requirement β -cell function declines. Latent Autoimmune Diabetes in Adulthood (LADA): Definition: A form of diabetes that shares features of both type 1 and type 2 diabetes, with a slower onset, usually diagnosed in adulthood. Key Characteristics: Characteristic Details Autoimmune Basis Presence of islet autoantibodies (e.g., GAD antibodies) indicating autoimmune β -cell destruction. Slower Progression Gradual β -cell destruction; patients may not initially require insulin but will eventually need it. Diagnostic Challenge Often confused with type 2 diabetes; islet autoantibodies help in distinguishing it. Key Considerations for LADA: Consideration Details Early Identification Timely recognition is essential for preserving β -cell function with early insulin initiation. Treatment Strategies Initially managed like type 2 diabetes (lifestyle changes, oral medications); insulin therapy needed later. Monitoring and Education Regular monitoring (glucose, HbA1c, islet autoantibodies) and patient education on self-management are crucial. Rapid β -cell destruction similar to type 1 diabetes (Option A): LADA progresses more slowly compared to classic type 1 diabetes. Absence of islet autoantibodies (Option B): Islet autoantibodies, particularly GAD antibodies, are present in LADA, indicating an autoimmune process. Complete management through lifestyle modifications and oral antidiabetic agents (Option D): While lifestyle modifications and oral agents may help initially, insulin therapy is eventually needed. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 730",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 4,
      "question": "Which of the following is required to diagnose complete remission of Type 2 Diabetes Mellitus (T2DM)?",
      "options": {
        "A": "HbA1c below 6.5% and fasting glucose between 100 and 124 mg/dL without treatment",
        "B": "HbA1c below 6.0% and fasting glucose below 100 mg/dL sustained without treatment",
        "C": "HbA1c below 7.0% and fasting glucose below 110 mg/dL with lifestyle modifications",
        "D": "HbA1c below 6.5% for at least six months without medication"
      },
      "correct_answer": "B",
      "explanation": "treatment remission, where normal blood glucose levels are maintained without medication. Remission of Type 2 Diabetes Mellitus (T2DM) Definition of Remission: Partial Remission: HbA1c < 6.5% (48 mmol/mol) and fasting glucose 100 - 124 mg/dL for at least one year without medication. (Option A ruled out) Complete Remission: HbA1c < 6.0% (42 mmol/mol) and fasting glucose < 100 mg/dL sustained without treatment. Factors Contributing to Remission: Weight Loss: Significant weight loss (e.g., 15% body weight) leads to remission in many patients. DiRECT trial: 85% of participants achieving significant weight loss entered remission. Bariatric Surgery: Results in major weight loss (up to 40 kg) with remission rates of 70–80%. Medications: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) aid in sustained weight loss, potentially leading to remission. Implications: Lifestyle modifications, bariatric surgery, and advanced medications shift the focus towards achieving remission, rather than merely managing T2DM symptoms. HbA1c below 7.0% and fasting glucose below 110 mg/dL with lifestyle modifications (Option C): These levels do not meet the criteria for complete remission, and the requirement for lifestyle modifications indicates ongoing management. HbA1c below 6.5% for at least six months without medication (Option D): The timeframe is insufficient, as complete remission requires at least one year without treatment. Reference: pmc.ncbi.nlm.nih.gov/articles/PMC7947138/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 5,
      "question": "A 25-year-old male with thalassemia major presents to the clinic with increased fatigue, joint pain, and symptoms of hyperglycemia. On examination, he has a discoloration of the skin as shown. His medical history includes multiple blood transfusions over the years. Which of the following is the most appropriate initial step in managing his condition?",
      "options": {
        "A": "Initiate a low-carbohydrate diet",
        "B": "Start iron chelation therapy",
        "C": "Begin insulin therapy",
        "D": "Schedule a follow-up for skin assessment"
      },
      "correct_answer": "C",
      "explanation": "blood transfusions in thalassemia major. This condition leads to impaired insulin secretion, resulting in hyperglycemia and characteristic skin changes. Bronze Diabetes: Definition: A form of diabetes associated with iron overload, commonly seen in patients with thalassemia. Characteristics: Named for the characteristic greyish skin discoloration due to excess iron deposits (hemosiderin staining). Underlying Mechanism: Caused by repeated blood transfusions in thalassemia management, leading to significant iron accumulation over time. Features of Bronze Diabetes: Feature Details Cause Primarily linked to thalassemia major Regular blood transfusions cause pancreatic iron overload, impairing insulin secretion Symptoms Typical diabetes symptoms (hyperglycemia) Joint pain and fatigue Skin changes less prominent in darker complexions Diagnosis Often after diabetic ketoacidosis Elevated blood glucose levels and serum ferritin indicating iron overload Management: Management Details Insulin Therapy Many patients require insulin for effective blood glucose management. Iron Chelation Therapy Helps reduce body iron levels, mitigating complications from iron overload. Regular Monitoring Continuous assessment of blood glucose and serum ferritin is crucial to prevent complications. Initiate a low-carbohydrate diet (Option A): While dietary management is important in diabetes, it is not the immediate initial step for a patient",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Endocrinology-Diabetes_Mellitus-I_Q5_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 6,
      "question": "Which of the following genetic factors is most strongly associated with an increased risk of developing Type 1 Diabetes Mellitus (T1DM) in Caucasians?",
      "options": {
        "A": "HLA-B27",
        "B": "HLA-DR3/DR4",
        "C": "CD25 gene mutations",
        "D": "SH2B3 gene polymorphisms"
      },
      "correct_answer": "B",
      "explanation": "Aetiology and Pathogenesis of Type 1 Diabetes Mellitus (T1DM): T1DM Overview: Autoimmune disease with T-cell-mediated destruction of insulin-secreting β cells in pancreatic islets. Involves insulitis (infiltration of islets by immune cells). Combination of genetic predisposition and environmental triggers is key. Anti-islet cell antibodies (ICA) are frequently found in Type 1 diabetes and are useful for diagnosing the condition, differentiating it from Type 2 diabetes, and identifying individuals at risk of developing Type 1 diabetes in the future. Genetic Predisposition: Monozygotic twins: 30–50% concordance rate. Dizygotic twins: 6–10% concordance rate. First-degree relatives: 1:20 risk vs 1:300 in the general population. HLA Region (Chromosome 6): DR3 and/or DR4 haplotypes linked to higher susceptibility in Caucasians. Other Genes: CD25, PTPN22, SH2B3, IL2RA, IL-10 involved in immune response. (Options C&D ruled out) Environmental Risk Factors for T1DM: Risk Factor Details Viral Infections Mumps, Coxsackie B4, Rubella (in utero), Cytomegalovirus, Epstein–Barr Chemicals/Drugs Nitrosamines (from smoked meats), coffee, BSA (bovine serum albumin) in cow’s milk Dietary Hypotheses Hygiene hypothesis (reduced exposure to microorganisms in early childhood might increase autoimmune disease susceptibility.) Low vitamin D levels Natural History of Type 1 Diabetes: Progressive β -cell destruction: Loss of first-phase insulin secretion. Glucose intolerance and undiagnosed diabetes before symptoms. Overt diabetes occurs when 80–90% of β -cell function is lost. Persistence of β Cells: Some β cells may persist even in long-standing T1DM cases. Variable rate of β -cell loss across individuals. HLA-B27 (Option A): Associated with autoimmune conditions like ankylosing spondylitis, not T1DM. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 728, 729",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 7,
      "question": "A 23-year-old man with a family history of diabetes presents with a diagnosis of MODY confirmed by genetic testing. He exhibits stable mild hyperglycemia and has normal renal function. Which of the following subtypes of MODY is most likely responsible for his condition?",
      "options": {
        "A": "MODY1",
        "B": "MODY2",
        "C": "MODY3",
        "D": "MODY5"
      },
      "correct_answer": "B",
      "explanation": "Correct answer: B) MODY2 Explanation: MODY2 is characterized by mutations in the GCK gene, leading to stable mild hyperglycemia without requiring treatment. Patients with this subtype typically maintain normal renal function and do not experience significant progression of diabetes. Understanding MODY MODY (Maturity-Onset Diabetes of the Young) A subtype of diabetes occurring in individuals under 25 years. Non-insulin-dependent and hereditary with autosomal dominant inheritance. Family history often spans three or more generations. Caused by various genetic mutations with multiple subtypes. Subtypes and Genetic Mutations MODY Subtypes Subtype Gene Mutated Key Features β -cell Glucose Sensing MODY2 GCK Mutations lead to altered glucose sensing. Results in mild, stable hyperglycemia. High fasting glucose; normal postprandial response. Rarely requires treatment; low risk of complications. β -cell Transcriptional Regulation MODY1 (Option A ruled out) HNF4 α Involves mutations affecting β -cell function. Progressive diabetes requiring treatment. MODY3 (Option C ruled out) HNF1 α Similar to MODY1 in progressive nature. Responds well to sulfonylureas. MODY5 (Option D ruled out) HNF1 β Associated with renal abnormalities (e.g., cystic disease). May cause genital malformations. Approximately 50% develop diabetes early in life. Importance of Recognizing MODY Tailored Treatment : Treatment can vary significantly based on genetic subtype. For example, MODY2 may not need medication, while HNF1 α and HNF4 α variants respond well to sulfonylureas. Prognosis and Complications : MODY2 generally has a favorable prognosis with low complication rates. Other subtypes may lead to progressive diabetes and higher complication risks. Genetic Counseling : Identifying MODY allows for targeted genetic counseling and testing for family members. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 733",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 8,
      "question": "A 55-year-old male with type 2 diabetes presents for a routine check-up. His medical history includes hypertension and smoking. Laboratory results show elevated LDL cholesterol levels. He is concerned about long-term complications of diabetes. Which of the following is the most important strategy to reduce his risk of macrovascular complications?",
      "options": {
        "A": "Tight glycaemic control only",
        "B": "Smoking cessation and statin therapy",
        "C": "Use of oral antihypertensives",
        "D": "Initiating low-dose aspirin therapy"
      },
      "correct_answer": "B",
      "explanation": "as myocardial infarction and stroke. Statin therapy is essential to lower LDL cholesterol, while smoking cessation significantly reduces cardiovascular risk. Macrovascular Complications of Diabetes Mellitus: Major causes of morbidity and mortality in type 1 and type 2 diabetes. Involves large blood vessels, leading to: Coronary circulation: Myocardial ischaemia/infarction. Cerebral circulation: Transient ischaemic attack, stroke. Peripheral circulation: Claudication, ischaemia. Key Points: Excess mortality : Mainly due to myocardial infarction and stroke. Accelerated atherosclerosis : Earlier onset and more severe in diabetics. Amplified risk factors : Smoking, hypertension, dyslipidemia. Metabolic syndrome : Common in type 2 diabetes, with additional cardiovascular risk factors due to insulin resistance. Criteria for metabolic syndrome are Hypertension, High Fasting glucose, Elevated TG, Low HDL, Central obesity. Statistics: Condition Increased Rate in Diabetics Cardiovascular death 1.7 times higher Myocardial infarction 1.8 times greater Stroke hospitalisation 1.5 times higher Non-traumatic amputations 60% occur in diabetics First cardiovascular event (type 1) 3 times higher in women, 2.3 times higher in men Mechanisms linking hyperglycemia to macrovascular disease: Increased vascular permeability : Due to high blood glucose. Lipoprotein deposition : Hyperinsulinemia and hypertension increase atherogenic lipoprotein deposits in large vessels. Risk Management: Glycaemic control : Reduces both microvascular and macrovascular complications. Blood pressure control : ACE inhibitors/ARBs are protective. Dyslipidemia management : Statins are recommended to lower cardiovascular risks. Lifestyle modifications : Smoking cessation, weight management, regular physical activity are crucial. Tight glycaemic control only (Option A) : While glycaemic control is important, addressing other risk factors like smoking and dyslipidemia has a more immediate impact on reducing macrovascular complications. Use of oral antihypertensives (Option C) : This alone may not be enough to reduce macrovascular risk, without addressing lipid levels and smoking, cardiovascular risk remains high. Initiating low-dose aspirin therapy (Option D) : Aspirin may help prevent cardiovascular events in high-risk individuals, but smoking cessation and statin use are more crucial in managing overall risk. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 743, 755, 756, 757",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 9,
      "question": "A 55-year-old patient with poorly controlled diabetes mellitus presents with various complications. Which of the following conditions is not classified as a microvascular complication of diabetes mellitus?",
      "options": {
        "A": "Thickening of capillary basement membranes",
        "B": "Increased vascular permeability",
        "C": "Development of diabetic foot ulcers",
        "D": "Retinal ischemia develops over time leading to neovascularization"
      },
      "correct_answer": "C",
      "explanation": "rather, it is a complication that can arise due to a combination of microvascular and macrovascular issues, including neuropathy and peripheral arterial disease. Diabetic Microvascular Complications Diabetic microangiopathy affects small blood vessels in diabetes, leading to significant morbidity and mortality. Key clinical syndromes include: Diabetic retinopathy Diabetic nephropathy Diabetic neuropathy Pathophysiology Prolonged hyperglycemia is believed to cause: Thickening of capillary basement membranes (Option A ruled out) Increased vascular permeability (Option B ruled out) Lipoprotein deposition in vessel walls (exacerbated by hyperinsulinemia and hypertension) Key Microvascular Complications Complication Pathophysiology and Characteristics Management Strategies Diabetic Retinopathy Prolonged hyperglycemia causes biochemical changes that damage retinal blood vessels. Thickening of the retinal capillary basement membrane occurs. Increased vascular permeability causing microaneurysms. Retinal ischemia develops over time, contributing to neovascularization. (Option D ruled out) Inflammatory mediators and oxidative stress Regular eye examination, laser therapy, and additional treatments as needed. Initial screening: Type I DM - 3 to 5 years after diagnosis Type II DM - at the time of diagnosis Screening is conducted annually, and if the results remain normal over time, it can be done once every two years. Diabetic Nephropathy Early stages : hyperfiltration Later stages: sustained proteinuria, nephrotic-range proteinuria, renal failure. Microalbuminuria predicts progression in type 1, less reliable in type 2. Aggressive blood pressure control (ACE inhibitors or ARBs), Lifestyle changes (diet, exercise), Possible renal replacement therapy in later stages Diabetic Neuropathy Axonal degeneration, schwann cell thickening, demyelination. Classifications include symmetrical sensory polyneuropathy, asymmetrical motor diabetic neuropathy, mononeuropathy, and autonomic neuropathy. Pain management (anticonvulsants, antidepressants, topical agents) and lifestyle modifications (glycemic control, exercise) to manage symptoms and slow progression Diabetic Foot Ulcers Trauma : Minor injuries can lead to ulceration Neuropathy : Loss of sensation causes unawareness of injuries. Structural foot changes , increasing pressure points and callus formation. Charcot neuroarthropathy: deformities in foot bones and joints. Peripheral Vascular Disease: Impaired blood flow hampers wound healing and raises infection and gangrene risk. (macrovascular complication) Callus Formation : Thickened skin areas can lead to necrosis beneath, resulting in ulceration. Patient Education: Educate patients on daily foot inspections, proper hygiene, appropriate footwear, and prompt care for minor injuries. Multidisciplinary Team Approach : Refer patients to a team including diabetes specialists, podiatrists, vascular surgeons, and orthotists for comprehensive care. Debridement and Infection Control: Remove necrotic tissue and administer timely antibiotic therapy to manage infections. Pressure Relief Strategies : Utilize custom insoles, orthotic footwear, total contact casts, or aircast boots to alleviate pressure on the ulcer. Revascularization and Amputation:",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 10,
      "question": "A 60-year-old man had an HbA1c of 6.1% during a routine check-up. He asks his physician about the best management strategy to prevent future progression of the disease. Which of the following is the most effective approach?",
      "options": {
        "A": "Starting medication immediately to control blood sugar levels",
        "B": "Undergoing bariatric surgery for weight loss",
        "C": "Implementing lifestyle modifications, including diet and exercise",
        "D": "Monitoring blood glucose levels without any other changes"
      },
      "correct_answer": "C",
      "explanation": "strategies for managing pre-diabetes (HbA1c: 5.7% - 6.5%) and preventing the onset of type 2 diabetes. Preventing Diabetes in Pre-Diabetic Individuals Key strategies for reducing the risk of progressing from pre-diabetes to type 2 diabetes and cardiovascular disease include: Strategy Key Points Healthy Eating Focus on a balanced diet, limiting total and saturated fats. Moderate carbohydrate intake ( ≤ 50% of daily calories) with < 11% from added sugars. Consider low glycemic index (GI) foods (e.g., whole grains, legumes). Aim for at least five servings of fruits and vegetables daily. Consult a registered dietitian for personalized advice. Weight Management Weight loss is crucial for overweight/obese individuals to improve glycemic control. Calorie restriction is essential for achieving weight loss. Regular Physical Activity Engage in at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise weekly. Include muscle-strengthening exercises twice a week. Minimize sedentary time (>90 minutes of inactivity). Seek guidance for managing exercise-related hypoglycemia, especially in individuals with type 1 diabetes. Alcohol Moderation Follow recommended alcohol intake guidelines to avoid hypoglycemia. Consume alcohol with food to mitigate risks. Smoking Cessation Quit smoking to lower the risk of cardiovascular disease and other health issues. Regular Monitoring Schedule regular checkups to monitor glucose levels, blood pressure, and lipid profiles. Manage cardiovascular risk factors aggressively. Consider early intervention with medications like metformin if necessary. Starting medication immediately to control blood sugar levels (Option A) Medication may be necessary for some individuals but is not the first line of management for pre-diabetes. Undergoing bariatric surgery for weight loss (Option B) Bariatric surgery is a more invasive option typically reserved for individuals with obesity and related complications, not solely for pre-diabetes. Monitoring blood glucose levels without any other changes (Option D) Monitoring blood glucose levels alone without making lifestyle changes will not effectively prevent diabetes progression. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 722, 726, 727, 728, 743, 744, 745.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 11,
      "question": "A 12-year-old girl presents with increased thirst, frequent urination, and fatigue over the past few weeks. Her parents mention that she has lost weight despite having a normal appetite. On examination, she appears dehydrated and has a fruity-smelling breath. Blood tests reveal a plasma glucose level of 350 mg/dL and a positive urine ketone test. Which of the following is true for this condition?",
      "options": {
        "A": "Auto-antibody present is anti-ICA",
        "B": "Increased fasting insulin levels",
        "C": "Polygenic cause",
        "D": "Due to recent hormonal changes"
      },
      "correct_answer": "A",
      "explanation": "occurs, often accompanied by the presence of islet cell autoantibodies (anti-ICA). Type of DM Characteristics Type 1 DM Pediatric onset Autoimmune destruction of >80% beta cells due to HLA association Leads to insulinopenia Auto-antibody: anti-ICA Risk of diabetic ketoacidosis (utilizes ketone bodies for energy) Type 2 DM Relative insulin resistance Increased fasting insulin levels (radioimmune insulin levels) (Option B) Polygenic cause (Option C) MODY (Maturity Onset Diabetes of the Young) Monogenic form Autosomal dominant inheritance pattern Expressed in every generation At least 2 consecutive generations with DM history It resembles Type 2 diabetes but usually occurs in younger individuals. Gestational Diabetes Mellitus (Option D) Defined as: 1. Plasma glucose > 140 mg/dL after 75g of glucose (WHO criteria) 2. After 100g glucose (Carpenter/Coustan diagnostic criteria - ADA criteria): 1 hr later, plasma glucose ≥ 180 mg/dL 2 hr later, plasma glucose ≥ 155 mg/dL 3 hr later, plasma glucose ≥ 140 mg/dL Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 3095",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 12,
      "question": "A 50-year-old woman presents for a routine check-up. She is overweight but has no family history of diabetes or hypertension. According to the American Diabetes Association (ADA) guidelines, what is the most appropriate screening recommendation for her?",
      "options": {
        "A": "No screening is necessary until age 60.",
        "B": "Screen now and re-screen every 3 years if normal.",
        "C": "Screen every year regardless of results.",
        "D": "Screen only if symptoms of diabetes appear."
      },
      "correct_answer": "B",
      "explanation": "screening for diabetes, regardless of risk factors. Since the patient is 50 years old, she should be screened now, with rescreening every 3 years if the results are normal, ensuring early detection and intervention if necessary. Diabetes Mellitus Screening Recommendations General Population Adults ≥ 45 years : Begin screening at 45, even without risk factors; repeat every 3 years if results are normal. Overweight/Obese Adults : Screen earlier if they have risk factors like family history, hypertension, or belong to high-risk ethnic groups. High-Risk Groups Prediabetes : Screen annually to monitor progression. High-Risk Ethnicities : Screen at a younger age (e.g., African Americans, Latinos, Native Americans, Asian Americans, Pacific Islanders). Gestational Diabetes Pregnant Women : Universal screening is recommended in the second trimester or earlier if risk factors exist. No screening is necessary until age 60 (Option A) : Screening should begin at age 45 regardless of other factors. Screen every year regardless of results (Option C) : Annual screening is only recommended for those with prediabetes. Screen only if symptoms of diabetes appear (Option D) : Screening should not wait for symptoms to appear, especially for at-risk individuals. Reference: https://www.ncbi.nlm.nih.gov/books/NBK574060/ https://www.ncbi.nlm.nih.gov/books/NBK554615/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 13,
      "question": "A glucagon-stimulated C-peptide test is performed on a patient receiving exogenous insulin therapy. Which of the following findings is most likely in a patient with long-standing type 1 diabetes?",
      "options": {
        "A": "Elevated serum C-peptide levels after glucagon stimulation",
        "B": "Decreased or absent serum C-peptide levels",
        "C": "Normal C-peptide levels but reduced blood glucose response",
        "D": "Elevated C-peptide levels with low insulin resistance"
      },
      "correct_answer": "B",
      "explanation": "β -cell function, resulting in low or undetectable C-peptide levels, even after stimulation. This differentiates it from type 2 diabetes, where C-peptide levels are typically higher. Glucagon-Stimulated C-Peptide Test Purpose : Assesses endogenous insulin production, especially in patients on exogenous insulin. C-Peptide C-peptide : A byproduct formed when insulin is cleaved from pro-insulin in pancreatic β cells. Structure : Pro-insulin = α -chain + β -chain + C-peptide. β -cell enzymes cleave C-peptide, leaving active insulin ( α and β chains) and free C-peptide. Detection : Measured via immunoassays in blood or urine. Uses of Glucagon-Stimulated C-Peptide Test Differentiates diabetes types : Low C-peptide → Long-standing type 1 diabetes. (Option B) High C-peptide → Severe insulin resistance. (Options A & D ruled out) Measures endogenous insulin in patients on exogenous insulin : Synthetic insulin lacks C-peptide, so serum C-peptide helps evaluate pancreatic insulin production. Aids in diagnosing hypoglycemia : Helps detect spontaneous hypoglycemia causes. Procedure for the Glucagon-Stimulated C-Peptide Test Step Description Baseline sample Draw blood to measure the initial C-peptide level. Glucagon injection Inject glucagon to stimulate insulin production. Follow-up samples Take blood samples at intervals (e.g., 30 & 60 minutes) post-injection. Analysis : Comparing C-peptide levels before and after stimulation helps assess pancreatic beta-cell function. Normal C-peptide levels but reduced blood glucose response (Option C): The glucagon-stimulated test primarily measures C-peptide to evaluate endogenous insulin production, not blood glucose directly. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 724, 727 .",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 14,
      "question": "A 56-year-old male with type 2 diabetes presents for a follow-up after recent medication changes. His physician wants to assess how well his blood glucose levels have been controlled over the past few weeks. Which of the following tests is the most appropriate for short-term monitoring of his glycemic control?",
      "options": {
        "A": "HbA1c",
        "B": "Fructosamine",
        "C": "Fasting Blood Glucose",
        "D": "Oral Glucose Tolerance Test (OGTT)"
      },
      "correct_answer": "B",
      "explanation": "average blood glucose levels over the past 2-3 weeks , allowing for timely adjustments in diabetes management. This is crucial when monitoring changes after medication adjustments, unlike HbA1c, which indicates longer-term control over 2-3 months. Fructosamine Testing: Clinical Significance Fructosamine : Formed by glucose binding to serum proteins (mainly albumin). Duration of Reflection : Reflects average glucose levels over the last 2-3 weeks . Advantages Short-Term Monitoring : Ideal for assessing recent glycemic changes. Unaffected by Hemoglobin Variants : Useful in cases like sickle cell disease or anaemia where HbA1c may be unreliable. Fast & Convenient : No fasting is required; serum/plasma samples are used. Reference Ranges Population Fructosamine Levels (µmol/L) Non-diabetic 200–285 Diabetic (poor control) Elevated above 285 Comparison to HbA1c : HbA1c reflects glucose over 2-3 months . (Option A ruled out) Comparison to Fasting, Postprandial Plasma Glucose and OGTT: Provide only single-time-point results. (Options C & D ruled out) Reference: www.ncbi.nlm.nih.gov/pmc/articles/PMC4604592/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 15,
      "question": "A 45-year-old obese woman with no acute symptoms presents for routine screening. Given her family history of diabetes, which diagnostic test would provide the most reliable indication of her glycemic status and aid in the early detection of diabetes?",
      "options": {
        "A": "Fasting Plasma Glucose (FPG)",
        "B": "Oral Glucose Tolerance Test (OGTT)",
        "C": "Random Plasma Glucose (RPG)",
        "D": "Glycated Hemoglobin (HbA1c)"
      },
      "correct_answer": "D",
      "explanation": "diagnosing diabetes in asymptomatic individuals. It provides a more comprehensive view of glucose levels compared to other tests, with a diagnostic threshold of ≥ 48 mmol/mol (6.5%), making it ideal for early detection, particularly in patients with risk factors like obesity and family history. HbA1c prediction: < 5.7% : Normal 5.7% - 6.5% : Pre-diabetic > 6.5% : Diabetic Investigating and Diagnosing Diabetes Mellitus Blood Glucose Tests: Fasting Plasma Glucose (FPG) (Option A ruled out) Measures glucose after an overnight fast. Diagnostic threshold: ≥ 126 mg/dL (7.0 mmol/L). Simple, cost-effective, and widely available. Random Plasma Glucose (RPG) (Option C ruled out) Measures glucose at any time, irrespective of meals. Diagnostic threshold: ≥ 200 mg/dL (11.1 mmol/L). Useful for immediate diagnosis in symptomatic patients. Oral Glucose Tolerance Test (OGTT) (Option B ruled out) Fasting glucose was measured, followed by a 75 g glucose drink, then re-measured after 2 hours. Diagnostic threshold: ≥ 200 mg/dL (11.1 mmol/L). More time-consuming; identifies impaired glucose tolerance. Important Considerations for Blood Glucose Testing Venous plasma values are more reliable for diagnosis. Capillary blood glucose (finger prick) results are not suitable for diagnosis due to variability. Glycated Hemoglobin (HbA1c): An Emerging Standard (Option D) Reflects average glucose levels over 2-3 months. Diagnostic threshold: ≥ 48 mmol/mol (6.5%) as per WHO. Not recommended for: Suspected type 1 diabetes or recent hyperglycemia. Pregnancy due to increased red blood cell turnover. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 722, 726, 727, 728.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 16,
      "question": "A 60-year-old male with a history of hypertension presents for a routine check-up. He has no symptoms but is concerned about his blood sugar levels. His lab results show: Fasting plasma glucose: 128 mg/dL (7.1 mmol/L) HbA1c: 6.7% What is the next best step?",
      "options": {
        "A": "Repeat fasting plasma glucose for confirmation",
        "B": "Perform an oral glucose tolerance test (OGTT)",
        "C": "Start lifestyle modifications and monitor for pre-diabetes",
        "D": "Diagnose diabetes mellitus and initiate treatment"
      },
      "correct_answer": "A",
      "explanation": "plasma glucose test, as a single elevated reading ( ≥ 126 mg/dL) is not sufficient for diagnosis without corroboration. This ensures accuracy and reduces the risk of false positives, guiding appropriate management. Diagnosing Diabetes Mellitus Diabetes Mellitus Diagnosis is based on confirming hyperglycemia through the following methods: Test Diagnostic Threshold for Diabetes Random plasma glucose ≥ 200 mg/dL Fasting plasma glucose ≥ 126 mg/dL Oral glucose tolerance test (OGTT) ≥ 200 mg/dL after 2 hours with 75 g glucose. OGTT is not necessary if fasting glucose is already in the diabetic range. (Option B ruled out) Glycated hemoglobin (HbA1c) < 5.7% : Normal 5.7% - 6.5% : Pre-diabetic > 6.5% : Diabetic Asymptomatic patients : Two positive tests (same method) are required for confirmation. (Option D ruled out) HbA1c Limitation : Not suitable for recent-onset diabetes (e.g., type 1 diabetes or severe hyperglycemia) as it reflects the past 2-3 months of glycemic control. Pre-diabetes: Pre-diabetes is characterized by elevated glucose levels but not meeting diabetic thresholds. Type Blood Glucose Range Impaired fasting glucose 110–125 mg/dL (6.1–6.9 mmol/L) (Option C ruled out) Impaired glucose tolerance Fasting < 126 mg/dL + 2-hour OGTT: 140–200 mg/dL (7.8–11.1 mmol/L). Pre-diabetes indicates a higher risk of progression to diabetes. Other Investigations: Investigation Purpose Islet Autoantibodies Indicates type 1 diabetes (autoimmune destruction). C-peptide Measurement Differentiates type 1 (low C-peptide) vs. severe insulin resistance (high C-peptide). Urine Protein Testing Detects microalbuminuria for nephropathy and cardiovascular risk. Lipid Profile Identifies dyslipidemia, a common comorbidity in diabetes. Liver and Thyroid Tests Detects abnormalities related to diabetes complications. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 722, 726, 727, 728.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 17,
      "question": "Which of the following drugs is most likely to cause drug-induced diabetes by impairing insulin secretion from the pancreas? D. β -lactam antibiotics",
      "options": {
        "A": "Glucocorticoids",
        "B": "Thiazide diuretics",
        "C": "Phenytoin"
      },
      "correct_answer": "B",
      "explanation": "hypokalemia induced by the thiazide diuretics), leading to increased blood glucose levels and a higher risk of developing diabetes. Drugs and Conditions Associated with Diabetes or Hyperglycemia Drugs That Can Cause Diabetes Drug Class Mechanism Key Note Glucocorticoids Increase insulin resistance (Option A ruled out) Can cause temporary or type 2 diabetes Thiazide diuretics Impair insulin secretion from the pancreas (Option B) Used to treat hypertension Phenytoin Possible liver-related mechanism (Option C ruled out) Anticonvulsant medication Drugs Affecting Glucose Levels but Not Directly Causing Diabetes Drug Effect β -lactam antibiotics Interfere with urine glucose tests (Option D ruled out) Levodopa May cause false-positive glucose results Salicylates Affect glucose measurements in urine Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 725, 728, 733 KD Tripathi, Essentials of Medical Pharmacology, 8th edition, Page 606.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 18,
      "question": "A 45-year-old man presents with complaints of progressive changes in his appearance over the past few years. He notes that his shoes no longer fit, and his wedding ring feels tight on his finger. His wife has remarked that he seems to have developed more pronounced facial features. He also reports excessive sweating and occasional headaches. On examination, there is noticeable frontal bossing. Which of the following complications is most likely associated with his condition?",
      "options": {
        "A": "Microglossia",
        "B": "Hypotension",
        "C": "Diabetes mellitus",
        "D": "High-pitched voice"
      },
      "correct_answer": "C",
      "explanation": "features and excessive sweating . Insulin resistance is a common complication due to elevated growth hormone levels, leading to impaired glucose metabolism and an increased risk of developing diabetes. Category Causes of Diabetes Description Pancreatic Damage Damage to the exocrine component of the pancreas Cystic fibrosis: common cause Causes diarrhea and steatorrhea due to malabsorption and DM manifestations. Chronic pancreatitis Insulinopenia occurs due to reduced beta cell mass. Lack of insulin leads to elevated blood sugar Endocrinopathies Acromegaly Increased growth hormone (GH) levels lead to insulin resistance. Pheochromocytoma Increased norepinephrine or epinephrine levels cause elevated blood sugar, palpitations, and sweating. Cushing's Syndrome Grossly elevated cortisol levels lead to insulin resistance and DM. Medications Steroids Long-term use can induce insulin resistance. Immunomodulators mTOR inhibitors and calcineurin inhibitors can affect glucose metabolism Thiazides Hydrochlorothiazide may cause elevated HbA1c values, leading to impaired glucose tolerance. Propranolol It can affect glucose metabolism, and it is used for migraine prophylaxis and anxiety management. Antipsychotics Some antipsychotic medications can lead to weight gain and insulin resistance. Microglossia (Option A): acromegaly typically causes macroglossia (enlarged tongue) Hypotension (Option B): is not typical in acromegaly, as patients usually have hypertension. High-pitched voice (Option D): this is incorrect because acromegaly often results in a deeper voice due to changes in the larynx. Reference: Classification of Diabetes Mellitus - Endotext - NCBI Bookshelf",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    },
    {
      "q_no": 19,
      "question": "Which of the following statements about Type 1.5 Diabetes Mellitus is incorrect?",
      "options": {
        "A": "Characterized by autoimmune destruction of beta cells",
        "B": "Patients are typically diagnosed in childhood",
        "C": "It is often misdiagnosed as Type 2 DM",
        "D": "C-peptide levels decline more slowly compared to Type 1 DM"
      },
      "correct_answer": "B",
      "explanation": "often in their 20s to 30s, distinguishing it from Type 1 DM which commonly presents in childhood. It characteristics of both Type 1 and Type 2 diabetes, which is why it is referred to as Type 1.5. Type 1.5 DM (LADA) Etiology: Similar to Type 1 DM due to autoimmune destruction of pancreatic beta cells. Age-wise Presentation: Resembles Type 2 DM because the beta cell destruction is gradual. Typically diagnosed in adults, often in their 20s to 30s. Antibodies: Presence of anti-GAD (glutamic acid decarboxylase) antibodies. Misdiagnosis: Frequently misdiagnosed as Type 2 DM due to adult onset. C-Peptide Levels: Decrease slowly compared to Type 1 DM, reflecting gradual beta cell loss. Treatment: It is initially managed similar to Type 2 diabetes, but as the progression of the condition is comparatively early, insulin therapy may eventually become necessary. Reference: www.ncbi.nlm.nih.gov/books/NBK557897/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-I"
    }
  ]
}
